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Objectives: In clinical trials of new cancer drugs, reliable data for progression-free
survival will often become available far sooner than reliable data for overall survival. The
aim of this study was to determine how many months it would be expected that any given
new drug for metastatic breast or colorectal cancer will add to overall survival times given
that the number of months the drug adds to progression-free survival times relative to a
standard drug is roughly already known.
Methods: A literature search was conducted over Medline for randomized controlled trials
(RCTs) published between January 1980 and August 2008 that assessed the effect of a
drug treatment in comparison to an alternative drug treatment on patients with either
metastatic breast or metastatic colorectal cancer.
Results: The literature search found 95 and 74 RCTs for metastatic breast and colorectal
cancer, respectively, that satisfied the study’s inclusion criteria. The results from these
trials are consistent, in the case of each of these two metastatic cancers, with gains in
time to disease progression being generally associated with no gains or with very slight
gains or losses in post-progression survival (i.e., the time between disease progression
and death).
Conclusions: It would appear that drugs for metastatic breast or colorectal cancer that
extend, by a given amount, the time period between the start of treatment and disease
progression (i.e., time to progression) have a strong tendency to extend, by roughly the
same amount, the period between the start of treatment and death (i.e., overall survival).
Keywords: Metastasis, Breast cancer, Colorectal cancer, Progression-free survival,
Overall survival
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In a clinical trial where a new treatment for cancer is being
compared with a standard or alternative treatment, it will
generally be the case that reliable data for disease-free or
progression-free survival will become available far sooner
than reliable data for overall survival. Therefore, despite the
fact that gains in overall survival may be the main outcome
of interest when deciding on whether or not to approve a new
treatment, this decision will often need to be made on the
basis of information relating to disease-free or progression-
free survival.
Furthermore, for deciding upon whether to make a new
drug freely available within a publicly funded health service
it is often the case, and is becoming more the case, that gains
in actual overall survival times, as measured through say the
median overall survival time, are of greater importance than
hazard ratios or relative risks for overall survival. This is
due to the fact that calculations involving QALYs (quality-
adjusted life-years) have become increasingly used in recent
years as the basis for deciding upon the cost-effectiveness
of new treatments. For example, in the United Kingdom,
the size of the gains in QALYs caused by a new treatment
is a critical factor in determining whether or not the treat-
ment is approved by NICE (National Institute for Clinical
Excellence).
The aim of this study is to attempt to determine how
many months it would be expected that a new drug will add
to overall survival times for metastatic cancer given that the
number of months the drug adds to progression-free survival
times relative to a standard drug is roughly already known.
This will be achieved by analyzing results from trials for
other drugs that have advanced sufficiently into their follow-
up periods such that median times for both progression-free
survival and overall survival are available.
The two types of metastatic disease that will be focused
upon are metastatic breast and metastatic colorectal cancer.
Breast cancer was chosen because, apart from nonmelanoma
skin cancer, it is the most common type of cancer within the
United Kingdom in terms of incidence (according to Cancer
Research UK 2005 data), and colorectal cancer was chosen
because it has become a standard cancer to examine with
regard to the general type of issue being addressed in the
present study (5;9;11;12;15).
A natural starting point for the present study is the work
of Johnson and colleagues in relation to metastatic colorectal
and non–small-cell lung cancer (9) and the work of Tang and
colleagues in relation to metastatic colorectal cancer (15).
Using results from past trials, these studies examined the ef-
fect on median overall survival of differences in median time
to disease progression between treatment and control groups.
The results from these studies demonstrated the existence of
a positive correlation between changes in overall survival and
changes in time to progression for both metastatic colorectal
cancer (with correlation coefficients of 0.3 and 0.52 for each
of these studies) and non–small-cell lung cancer (with corre-
lation coefficient of 0.6). However, the existence of a positive
Table 1. String Combinations Used in the Lit-
erature Search (At least one item from both
lists A and B).
List A List B
“breast” “metastatic”
“colorectal” “metastasis”
“colon” “metastases”
“large bowel” [“advanced” AND “cancer”]
correlation between changes in these two variables simply
suggests that gains in time to progression do not completely
disappear during the time between disease progression and
death, that is, an x month gain in time to progression is not
reduced, on average, to a zero gain in overall survival. In par-
ticular, the existence of this positive correlation is consistent
with any of the following three theories being true: Theory 1.
Increases in median time to progression (TTP) most com-
monly lead to increases in the time from disease progression
to death, that is, the post-progression survival time. Theory 2.
Increases in median TTP generally lead to little change in
post-progression survival. Theory 3. Increases in median TTP
most commonly lead to decreases in post-progression sur-
vival.
If it could be resolved which of these three theories is
true, then it would be possible to know whether an x month
gain in time to progression generally leads to more than an
x month gain in overall survival (Theory 1), to roughly an
x month gain in overall survival (Theory 2) or to less than
an x month gain in overall survival (Theory 3). Following on
from a previous preliminary study (2), the aim of the present
study is assess the degree of support for each of these three
theories.
METHODS
A literature survey was conducted over Medline for random-
ized controlled trials (RCTs) of treatments for metastatic
breast and metastatic colorectal cancer published between
January 1980 and August 2008. In particular, articles were
searched that had been identified as being RCTs through the
work of the Cochrane Collaboration (8). The string combina-
tions searched for over all fields consisted of one item from
both lists A and B in Table 1. Articles had to be written in
English. For trials found through this search, the inclusion
criteria for this study were as follows:
(i) Patients included in the trial either all had to have distant
metastatic disease (Stage IV or Dukes D disease) or at least a
proportion of the patients had to have distant metastatic disease
with the rest of the patients having locally advanced disease
(Stage III or Dukes C disease).
(ii) A drug treatment had to be administered to both the treatment
and control groups. The drug or combinations of drugs given
to the treatment group had to be different from the drug or
208 INTL. J. OF TECHNOLOGY ASSESSMENT IN HEALTH CARE 27:3, 2011
Progression-free versus overall cancer survival
0 50 100 150 200
Percentage gain in median time to progression (TTP)
Pe
rc
en
ta
ge
 c
ha
ng
e 
in
 p
os
t−
pr
og
re
ss
io
n 
su
rv
iva
l
20
0
10
0
0
10
0
20
0
(c)
(b)
(d)
(a)
(e)
1
3
2
Fa
vo
ur
in
g 
tre
at
m
en
t
Fa
vo
ur
in
g 
co
nt
ro
l
Figure 1. Guide to theories and hypotheses being tested.
combination of drugs given to the control group. Any other
interventions had to be applied in the same manner to both
the treatment and control groups. Note that trials that compare
drug treatments with no treatment or with different doses of the
same drugs or with treatments involving non-pharmaceutical
interventions were excluded. This was done to maintain rele-
vance to the scenario where a regulatory or funding body has
to decide between an existing standard drug therapy and a new
alternative drug therapy.
(iii) The median time to disease progression and the median overall
survival time had to be reported for both the treatment and
control groups somewhere in the full article if the publication
year was 1995 or later or in the abstract of the article if the
publication year was earlier than 1995.
As well as median values for time to progression and
overall survival for both control and treatment groups being
extracted, the p-value for the change in time to progression
based on the log-rank test was also recorded for each trial
found by the literature search where it was available. This
was done to assess the statistical significance of treatment
effects in the various trials. The focus of the analysis was
on p-values for treatment differences in terms of time to
progression rather than in terms of overall survival due to
the fact that a negligible change in median overall survival
is consistent with the scenario where a substantial gain in
median time to progression is combined with a substantial
fall in post-progression survival or vice-versa. This type of
scenario would obviously be of interest given the types of
hypothesis being tested.
If a trial contained two treatment groups (A and B) and a
control group, then the only treatment comparisons included
in the study were against the control group, that is, a direct
comparison between the groups A and B was excluded. This
was done because of the high degree of interdependence be-
tween treatment comparisons that would have resulted if this
latter comparison had been included. If one of the treatment
groups was not clearly defined as being the control group,
then the control group was chosen to be the last group for
which the median time to progression was reported.
As already stated, the aim of this study was to assess the
degree of support for the three theories outlined in the Intro-
duction. These three theories are illustrated in Figure 1. Post-
progression survival was defined as the difference between
median overall survival and median time to progression. To
allow standard statistical tests to be performed, these three
theories were assessed within the context of several specific
hypotheses.
With regard to Theory 1 (that increases in median
TTP most commonly lead to increases in post-progression
survival), we tested whether percentage gains in post-
progression survival (PPS) are greater than or equal to (as
opposed to less than) percentage gains in median TTP (e.g.,
median TTP increases from 8 to 12 months and PPS increases
from 12 to at least 18 months) and whether percentage gains
in PPS are greater than or equal to half of the percentage
gains in median TTP (e.g., median TTP increases from 8 to
12 months and PPS increases from 12 to at least 15 months).
The first of these two hypotheses corresponds to line (a) in
Figure 1 and the second hypothesis corresponds to line (b).
With regard to Theory 2 (that increases in median TTP gen-
erally lead to little change in PPS), we tested whether there
are no gains or losses in PPS (which corresponds to line
[c] in Figure 1). With regard to Theory 3 (that increases in
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median TTP most commonly lead to decreases in PPS), we
tested whether percentage losses in PPS are greater than or
equal to (as opposed to less than) percentage gains in median
TTP (which corresponds to line [e] in Figure 1) and whether
percentages losses in PPS are greater than or equal to half of
the percentage gains in median TTP (which corresponds to
line [d] in Figure 1).
Note that these hypotheses are based on percentage
changes in survival times rather than absolute changes in
survival times. This was done to be consistent with the ac-
cepted principle of meta-analysis that the best measures of
effect size for forming combined estimates are those that are
independent of trial baseline measures, especially when such
measures would be expected to vary substantially between
trials, for example, baseline or control survival rates.
Results for the treatment comparisons found by the lit-
erature search were plotted in the type of diagram given in
Figure 1. For ease of graphical presentation, this type of di-
agram is set up so that the decision on whether to look at
changes in going from control to treatment or treatment to
control is made to ensure that the change in median TTP
is always positive. Therefore, in terms of Figure 1, the me-
dian TTP for the treatment group can never be less than the
median TTP for the control group. If there was exactly no
difference in median TTP between the control and treatment
groups then the treatment comparison concerned would carry
no information regarding the relationships between changes
in median TTP and changes in post-progression survival that
are under investigation. Therefore, these treatment compar-
isons were not included in the main analysis.
In order for gains in post-progression survival to be
illustrated in a way that is symmetrical to losses in post-
progression survival, the vertical axis in Figure 1 is defined
differently either side of the level representing no change in
post-progression survival. In particular, if for any treatment
comparison, there is a percentage increase in PPS in going
from control to treatment, then this increase is plotted above
the “no change” level, whereas if there is a decrease in PPS
in going from control to treatment, then the percentage in-
crease in PPS in going in the opposite direction, that is, from
treatment to control, is plotted below the “no change” level.
Theories 1 to 3 outlined in the Introduction were sta-
tistically tested using Spearman’s rank correlation test and
the sign test. In particular, Spearman’s rank correlation test
was used to test for the presence of positive or negative
correlations between percentage gains in median TTP and
percentage changes in PPS. The sign test was used to mea-
sure the support for the statistical hypotheses outlined above,
that is, the hypotheses that correspond to lines (a) to (e) in
Figure 1. The test statistic for the sign test was the number of
treatment comparisons that lie above the line associated with
the given hypothesis, as illustrated in Figure 1, divided by
the number of comparisons that lie below this line. This test
was performed under the null hypothesis that the population
value for this test statistic equals one.
RESULTS
The number of RCTs found by the literature search that satis-
fied the given inclusion criteria was 95 and 74 for metastatic
breast and colorectal cancer, respectively, of which 77 and
69, respectively, were published in the period 1995 to 2008
(and, therefore, for which survival times not reported in the
abstract were searched for in the full article). Moreover, from
all the RCTs found, the number of individual treatment com-
parisons that satisfied the inclusion criteria and that qual-
ified as being sufficiently independent to be included (ac-
cording to the given exclusion criteria) was 102 and 85 for
breast and colorectal cancer, respectively. The number of
these treatment comparisons for which there was exactly no
difference in median time to progression between the con-
trol and treatment groups was four and seven for breast and
colorectal cancer, respectively. This meant that 98 compar-
isons for breast cancer and 78 comparisons for colorectal
cancer entered into the main analysis. The references for
these studies are given in Supplementary Tables 1 and 2,
which can be viewed online at www.journals.cambridge.org/
thc2011013.
Figures 2 and 3 are plots of the percentage change in
post-progression survival against percentage gain in median
time to progression between the control and treatment groups
for metastatic breast and colorectal cancer, respectively. The
type of diagram used in these figures is the same as the type
of diagram discussed earlier that is shown in Figure 1. Each
point in Figures 2 and 3 represents a treatment comparison
included in the study, with the style and shade of the points
indicating the statistical significance level of the difference
in time to progression between the control and treatment
groups.
It can be seen that, for both Figures 2 and 3, the
points cluster more around line (c) than lines (a), (b), (d)
and (e). This implies greater support for Theory 2 (that in-
creases in median TTP generally lead to little change in post-
progression survival) than for the theory that increases in
median TTP commonly lead to substantial gains or losses in
post-progression survival (which is consistent with Theories
1 and 3).
This graphical analysis is backed up by the results of a
statistical analysis. In particular, for both metastatic breast
and colorectal cancer there is no statistical evidence to sug-
gest that percentage changes in PPS are correlated with per-
centage changes in median TTP (as indicated by the Spear-
man rank correlation test producing p-values of .37 and .11
for breast and colorectal cancer, respectively). This conclu-
sion is not affected by whether or not the analysis is re-
stricted only to treatment comparisons where the change in
time to progression is statistically significant at the 5 per-
cent level of significance (as indicated by the Spearman
rank correlation test for this restricted analysis producing
p-values of .78 and .54 for breast and colorectal cancer, resp-
ectively).
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Figure 2. Trial results for metastatic breast cancer.
If the hypothesis that increases in median TTP lead to
no gains or losses in PPS (which corresponds to line [c] in
Figure 1) is directly assessed by using the sign test then it
is not rejected at the 5 percent level of significance for ei-
ther breast or colorectal cancer (with p-values of .08 and .57,
respectively). On the other hand, if the hypothesis that per-
centage gains in PPS are greater than or equal to half of the
percentage gains in median TTP (which corresponds to line
[b] in Figure 1) and the hypothesis that percentage losses in
PPS are greater than or equal to half of the percentage gains
in median TTP (which corresponds to line [d] in Figure 1) are
separately assessed by the sign test then these two hypotheses
are rejected at the 0.1 percent level of significance for both
breast and colorectal cancer. The results of these sign tests,
therefore, imply greater support for Theory 2 than for the
theory that increases in median TTP commonly lead to sub-
stantial gains or losses in post-progression survival (which is
consistent with Theories 1 and 3). Again the conclusions of
this statistical analysis are not sensitive to whether or not the
analysis is restricted only to treatment comparisons where
the change in time to progression is statistically significant at
the 5 percent level of significance (i.e., for both cancers, the
former hypothesis is still not rejected at the 5 percent level of
significance while the latter two hypotheses are still rejected
at the 0.1 percent level of significance).
Over all treatment comparisons, the average percentage
change in median TTP from control to treatment (which is
always a gain under the definitions being used) is 36 percent
and 32 percent for breast and colorectal cancer, respectively.
By inverting the sign test and assuming a stable linear rela-
tionship between percentage changes in PPS and percentage
changes in median TTP, it can be stated with a 95 percent
confidence level that a 36 percent increase in median TTP for
metastatic breast cancer would result, on average, in percent-
age changes in PPS lying somewhere between gains limited
to 10.7 percent or losses limited to just 0.3 percent. By apply-
ing the same assumptions to the data for colorectal cancer,
it can be stated with a 95 percent confidence level that a
32 percent increase in median TTP for this metastatic cancer
would result, on average, in percentage changes in PPS lying
somewhere between gains limited to 9.8 percent or losses
limited to 4.4 percent. There is good evidence, therefore, that
if changes in post-progression survival are not, on average,
very small compared relative to changes in median TTP, they
will at least be in the same direction as changes to median
TTP. As a result, it can be concluded that, if gains in overall
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Figure 3. Trial results for metastatic colorectal cancer.
survival are not, on average, similar to gains in median TTP,
they will be at least as large as gains in median TTP.
Over all trials and treatment groups, the average time to
progression for metastatic breast cancer is 6.9 months and
the average time to death is 20.6 months. For metastatic col-
orectal cancer, average time to progression is 6.0 months and
average overall survival is 14.4 months. On the basis of these
average survival times, the dotted curves in Figures 2 and 3,
indicate the losses in post-progression survival that are re-
quired so that gains in median TTP are, on average, canceled
out; that is, overall survival does not increase despite gains in
median TTP. The percentage of treatment comparisons that
lie above these curves, and are, therefore, consistent with
overall survival increasing as a result of an increase in median
TTP, is 85 percent and 83 percent for breast and colorectal
cancer, respectively, and is 95 percent and 97 percent, re-
spectively, with regard to only treatment comparisons where
the change in TTP is statistically significant at the 5 percent
level. According to the sign test, the percentage of treatment
comparisons lying above these curves is statistically greater
than 50 percent at the 0.1 percent level of significance in all
these instances.
Figures 2 and 3 both contain a small number of outlying
points. For the treatment comparison labeled as point 1 in
Figure 2 (which corresponds to study 59 in Supplementary
Table 1), the median TTP is 5.5 and 6.4 months for the control
and treatment groups, respectively, whereas PPS is 11.8 and
4.9 months, respectively. For point 3 in Figure 2 (study 81 in
Supplementary Table 1), median TTP is 3.0 and 6.3 months
for the control and treatment groups, respectively, whereas
PPS is 8.1 and 4.1 months, respectively. Finally, for point 2
in Figure 3 (study 61 in Supplementary Table 2), the median
TTP is 4.2 and 7.2 months for the control and treatment
groups, respectively, whereas PPS is 3.0 and 8.7 months,
respectively.
However, the interpretation of these three outlying points
perhaps should be made in the light of additional relevant
information. In particular, the vertical positions of point 1
in Figure 2 and point 2 in Figure 3 have been determined
using overall survival data that are based on a very small
number of patients with the result that the confidence inter-
vals for median overall survival in these two cases are very
wide. Furthermore, point 3 in Figure 2 is one of three treat-
ment comparisons for metastatic breast cancer based on a
cross-over trial design where patients in the treatment group
switch to the control treatment at the point of disease pro-
gression and vice-versa. The outcome for point 3 is consis-
tent with patients who did not receive the better treatment in
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the progression-free phase benefitting from this treatment in
the post-progression phase. Note that none of the treatment
comparisons for metastatic colorectal cancer are based on
cross-over trials.
DISCUSSION
On the basis of an analysis of past trial results, it would
appear that drugs for metastatic breast or colorectal cancer
that extend, by a given amount, the time period between
the start of treatment and disease progression (i.e., time to
progression) have a strong tendency to extend, by roughly
the same amount, the period between the start of treatment
and death (i.e., overall survival).
One of the main strengths of the approach that has been
used is that relationships have been analyzed between actual
survival times and not between the hazard ratios or rela-
tive risks for progression-free and overall survival as has
been done in previous studies (1;3;4;5;7;10;12;13). This has
allowed direct conclusions to be drawn with regard to the
kind of outcome variables, for example, time to progression
in months and overall survival in months, that are of great
importance to both clinicians and policy makers. In addi-
tion, this study has not examined relationships in outcome
variables within only the control or treatment groups as has
been done by other researchers (6;11;14) but relationships
in the differences in outcome variables between treatment
and control groups. Therefore, this study is relevant to the
type of scenario where a decision needs to be made about
the efficacy of a new treatment in relation to an established
treatment.
The main weakness of this study is that it is of course
based on a retrospective analysis. Therefore, the conclusions
that have been drawn do not take account of the possible ar-
rival in the future of a new class of treatments for metastatic
cancer for which the relationship between time to progres-
sion and overall survival does not fit into the pattern reported
within this study. The conclusions of this study also do not
take account of future changes in practices and policies with
regard, for example, to how rapidly and frequently patients
are switched between treatments due to drug resistance. In
response to this though, it should be noted that the results
presented in this study are not tied to a particular philosophy,
policy, or drug treatment but instead are based on the vari-
ous practices, policies, and drug treatments that have been
employed in treating metastatic breast or colorectal cancer
since the 1980s.
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